HC Wainwright Issues Positive Forecast for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at HC Wainwright upped their Q1 2026 EPS estimates for Agenus in a research report issued to clients and investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn $2.10 per share for the quarter, up from their previous estimate of $1.45. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at $2.10 EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($1.54) EPS, FY2029 earnings at ($1.02) EPS and FY2030 earnings at ($0.11) EPS.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.83. The business had revenue of $34.20 million during the quarter, compared to analysts’ expectations of $28.10 million. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.

A number of other equities research analysts have also recently weighed in on AGEN. Wall Street Zen cut Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.50.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $3.33 on Friday. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34. The stock has a 50 day moving average of $3.20 and a 200-day moving average of $3.69. The company has a market capitalization of $127.87 million, a P/E ratio of -7.24 and a beta of 1.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the fourth quarter worth $31,000. R Squared Ltd acquired a new position in shares of Agenus in the fourth quarter valued at about $41,000. Redwood Family Wealth LLC bought a new position in Agenus during the fourth quarter worth about $44,000. Traynor Capital Management Inc. bought a new position in Agenus during the third quarter worth about $50,000. Finally, Quadrature Capital Ltd acquired a new stake in Agenus in the 4th quarter worth about $54,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus News Roundup

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Zacks upgraded AGEN to a Zacks Rank #1 (Strong Buy), signaling increased analyst optimism that may attract buyer interest and momentum traders. All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
• Positive Sentiment: Zacks flagged rising earnings estimate revisions as a reason AGEN could move higher — reinforcing the upgrade and suggesting analyst models are shifting toward better near‑term results. Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
• Positive Sentiment: HC Wainwright materially raised several near‑term EPS forecasts (notably Q1 and full‑year FY2026), lifting quarter and FY2026 estimates — a catalyst that can re‑rate the stock if investors believe earnings will improve meaningfully. (Research note summaries)
• Positive Sentiment: Clinical progress: Agenus announced first patient enrolled in the global Phase III BATTMAN trial (BOT+BAL) for MSS/pMMR metastatic colorectal cancer — Phase III starts and patient accrual milestones are commonly positive near‑term catalysts. Agenus enrols first patient in BATTMAN Phase III trial
• Positive Sentiment: Scientific visibility: Data from a Phase II investigator‑initiated study of BOT+BAL with agenT‑797 will be presented at AACR 2026 — upcoming conference exposure can boost investor confidence ahead of or after poster/oral presentation. Agenus Announces Data from Phase II Study … to be Presented at AACR 2026
• Neutral Sentiment: Zacks published broader pieces framing AGEN as a momentum/value/growth idea and compared sector performance — useful for traders but less likely to move the stock materially on its own. Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
• Negative Sentiment: HC Wainwright trimmed some longer‑range estimates (FY2029 and FY2030) even as it lifted near‑term numbers — a reminder that longer‑term profitability remains uncertain and could limit sustained multiple expansion if future guidance weakens. (Research note summaries)

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.